ReviewInternational journal of nanomedicine2026
Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This manuscript explores the innovative application of nanotechnology in the diagnosis and treatment of hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality worldwide. Emphasizing the synergistic potential of nanotechnology, the paper discusses advanced nanomaterials and techniques, such as targeted drug delivery systems, nanoparticle-based imaging, and multi-modal therapy, which enhance the precision and efficacy of HCC interventions. Nanotechnology offers significant improvements in early diagnosis through enhanced imaging capabilities and tumor-specific biomarkers, enabling more accurate detection of HCC at its early stages. Furthermore, it enables the development of novel therapeutic strategies, including the targeted delivery of chemotherapeutic agents, gene therapies, and immunotherapies, minimizing side effects and improving patient outcomes. The manuscript also highlights challenges such as bio-barrier penetration, biocompatibility, and the high production costs associated with nanomedicine. Despite these obstacles, the integration of nanotechnology with artificial intelligence and personalized medicine promises a transformative future for HCC treatment. This review underscores the pivotal role of nanotechnology in advancing both the diagnostic and therapeutic landscapes for HCC, offering a new frontier for improving survival rates and quality of life for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.